Nasdaq Biotechnology Ishares ETF (IBB)
$125.89
1.08 (0.85%)
IBB Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
1.44M
Day's Range
$125.87 - $127.62
52-Week Range
$111.83 - $141.16
Dividend & Yield
$0.61 (0.49%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
4 Top Stock Trades for Wednesday: AAPL, TGT, RIDE, IBB
Apple, Target, Lordstown Motors and the iShares Nasdaq Biotechnology ETF (IBB) were our top stock trades for Wednesday.
Which Biotech Stocks Are a Buy on Earnings?
If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.
A New Healthcare Stock Pick in the Industry of the Decade
This company is riding a powerful trend in the future of healthcare. Plus, it offers high growth, a huge potential market and a path to profitability.
Biotech Stocks Have Been on Fire, But Timing Is Everything
Consensus is that the experts will find a vaccine to Covid-19 soon, so the biotech stocks have rallied hard. Buying them now carries risk.
Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
First-Mover Advantage Will Benefit Amarin Stock More Than You Think
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
The Top Performing Sector in 2020 Will Be …
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
